Tagged: 483

The Importance of Information-Flow: The Case of the Thwarted Startup

In my last post, I discussed the cultural problem of excessive risk-aversion preventing pharma and CROs from using methods that could improve R&D productivity. This issue is never more evident than when applied to the critical area of information flow and decision making. Here’s an example of how a potentially important drug failed in a… Read more »